Abstract: A fragrance composition composed of a high-performance fragrance component and isopropyl myristate is provided. Use of isopropyl myristate as a solvent provides for an increase in the perceived fragrance intensity of a fabric care product, in particular under dry stage conditions.

Abstract: A method of diminishing the appearance of or effecting the removal or disappearance of seborrheic keratoses by the application of compositions containing a) one or more, preferably a combination of, dietary antioxidants and/or antioxidant sources, b) one or more hydrating agents and c) one or more keratolytic agents.

Abstract: Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (SLE) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a PD1 ligand.

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

Abstract: Methods and cleaning compositions for reduction of nucleic acid contamination on surfaces, in air, and in solutions using modified pectin are provided.

Abstract: Antimicrobial compositions having bactericidal activity are described. Also described is a method of treating bacterial infections using compositions comprising antimicrobial peptides or variants thereof.

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

Abstract: The method includes first adding at least one first chelator to smokeless tobacco, second adding at least one first antioxidant to the smokeless tobacco, the at least one first antioxidant being different than the at least one first chelator, and third adding at least one first flavorant to the smokeless tobacco, wherein the first adding occurs before the third adding.

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

Abstract: In one aspect, the invention provides compounds and methods that are useful for treating bacterial infections:

Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.

Abstract: A fusion protein is provided, comprising i) a biologically active polypeptide; and ii) a half-life extending polypeptide moiety comprising 2-80 units independently selected the amino acid sequences according to SEQ ID NO: 1: X1-X2-X3-X4-X5-X6-D-X8-X9-X10-X11 (SEQ ID NO: 1) in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The half-life extending polypeptide moiety has a generally unfolded conformation and provides a fusion protein with a large hydrodynamic radius that may avoid renal clearance. As a result, the biological half-life of the fusion protein is increased and the biological effect of the biologically active polypeptide may thus be prolonged.

Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumour or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.

Abstract: A nanoporous polymer membrane with vertically aligned pore channels can be synthesized through self-assembly of amphiphilic block copolymers on a supporting substrate. The pore surface chemistry can be functionalized for selective anion transport.

Abstract: An improved therapeutic adhesive patch for application to the heel is described for treating or preventing heel disorders or conditions, such as cracked heel.

Abstract: Aspects of the present invention relate to peptides having antimicrobial activity. In certain aspects, the invention relates to peptides having potent antimicrobial activity, broad-spectrum antimicrobial activity, and/or the ability to kill otherwise antibiotic-resistant microbes, or microbes protected by biofilms.

Abstract: The invention relates to methods of treating a fungal infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising one or more antifungal peptides selected from the group consisting of BmKn2, dBmKn2, Kn2-7, and dKn2-7. Antifungal pharmaceutical compositions and dosage forms, including field-deployable dosage forms, comprising one or more of these antifungal peptides are also contemplated herein.

Abstract: Disclosed are hypersensitive-response eliciting peptides that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.

Abstract: The disclosure relates to methods of prophylactic and therapeutic treatments of a Pneumocystis infection (i.e., an infection caused by Pneumocystis jirovecii) in a subject by administering to the subject a compound of any of formulas (I)-(III) (e.g., a salt of Compound 1, or a neutral form thereof). The disclosure also relates to methods of inhibiting the replication of a Pneumocystis spp. The methods of the disclosure can be useful in immunocompromised subjects.

Abstract: The present invention provides a nano-particle based structure or composition for a combinational cancer therapy. The structure has a doxorubicin (DOX) physically loaded on core-shell silver polymeric nanoparticles (AgN-Ps) with a ratio of 3.3-5.5% doxorubicin to 1% silver to 2-10% polymer. This structure enhances the cellular uptake of DOX in comparison to the current conventional combination therapy. The DOX-loaded nano-particles result in an improved the therapeutic efficiency of DOX, and reduced its toxicity, which cannot occur in case of adding DOX and AgNPs.

Abstract: The present invention concerns Thymosin alpha 1 for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

Abstract: The present invention relates to a composition comprising an aqueous continuous phase; a first dispersed phase which comprises styrene-maleimide copolymer particles; and a second dispersed phase which is either oil droplets, suspended particles or a capsule suspension; and to use of those compositions to control agricultural pests or diseases. It also relates to use of such compositions where rainfastness is important.

Abstract: The invention provides semisynthetic N-substituted derivatives of the antifungal antibiotic Amphotericin B and water soluble salts and complexes, pharmaceutical compositions and plant and building treatment products comprising the derivatives and their use as antifungal antibiotics.

Abstract: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

Abstract: A high purity cyclopeptide crystal has a structure shown by Formula I. R represents H or a cation forming a pharmaceutically acceptable salt. Also disclosed are a preparation method and a use of the high-purity cyclopeptide crystal.

Abstract: The present invention relates to a compound of formula (I) AA-AA-AA-R1—R2 (I) wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; R1 is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group, which group may incorporate up to 2 heteroatoms selected from N, O and S; and R2 is an aliphatic moiety having 2-20 non-hydrogen atoms, said moiety being linear, branched or cyclic. The invention further relates to formulations containing these compounds, solid supports having these compounds attached thereto, the use of these compounds in therapy, particularly as antimicrobial, anti-tumor or anti-biofilm agents and non-therapeutic uses of these compounds, particularly their use in inhibiting biofilm formation or removing a biofilm.

Abstract: Provided is a method for preparing a compound represented by Formula I or a salt thereof, wherein Coleophoma empetri F-11899 (FERM BP2635) and/or a mutant strain thereof is cultured in a medium containing amino acid or a salt thereof, an insoluble organic source, and a sugar alcohol, to produce the compound of Formula I or a salt thereof.

Abstract: Disclosed are a high purity of caspofungin or salts thereof, and a preparation method thereof, and use thereof. Disclosed are a caspofungin or salts thereof with low solvent residue and hyposaline, and a preparation process comprising: dissolving a crude product of caspofungin or salts thereof into a system of water and acetic acid, then mixing with a first organic solvent ethyl alcohol, subsequently mixing with a second organic solvent ethyl acetate, then being subject to filtration and drying together with water, to obtain caspofungin or salts thereof with high stability, low solvent residue and hyposaline.

Abstract: The present invention relates to a composition comprising caspofungin or a pharmaceutical acceptable salt thereof and succinate or lactate as a buffering agent.

Abstract: The invention features echinocandin class compounds. The compounds can be useful for the treatment of fungal infections.

Abstract: Disclosed is a low impurity content caspofungin pharmaceutical composition and a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition comprises the compound of formula I and/or a pharmaceutically acceptable salt thereof, in combination with a saccharide protective agent(s) and an amino acid(s). The caspofungin pharmaceutical composition is prepared by dissolving the saccharide protective agent and the amino acid into water or a suitable buffer solution; adding the caspofungin compound and dissolving it; filtering the solution and lyophilizing.

Abstract: Disclosed is a low impurity content caspofungin pharmaceutical composition and a method for preparing the low impurity content caspofungin pharmaceutical composition. The caspofungin pharmaceutical composition comprises the compound of formula I and/or a pharmaceutically acceptable salt thereof, in combination with a saccharide protective agent(s) and an amino acid(s). The caspofungin pharmaceutical composition is prepared by dissolving the saccharide protective agent and the amino acid into water or a suitable buffer solution; adding the caspofungin compound and dissolving it; filtering the solution and lyophilizing.

Abstract: The current invention relates to the use of a peptide comprising an amino acid sequence in the preparation of a medicament for the regeneration of tissue, preferably for the treatment of a wound. Further the invention relates to compositions comprising such peptides, and use of said peptides in both medical and nonmedical (cosmetic) applications.

Abstract: A 23 amino acid peptide, AtPep1, plays an important role as a signaling component of the innate immune system of Arabidopsis. The peptide precursor gene is transcribed in response to elicitors generated by pathogens, and AtPep1 is produced to amplify the signaling pathways. Seven paralogs of the AtproPep1 gene have been identified in the Arabidopsis genome, and orthologs have been identified in species of several agriculturally important families. AtPep1 and its paralogs and orthologs play important roles as endogenous signals to amplify innate immunity. The sequences of two AtPep1 receptors from Arabidopsis are also provided.

Abstract: The present invention provides methods for limiting development of skin wounds, and also for treatment of one or more of erythemas, blisters, rashes, pruritis, contact dermatitis, psoriasis, eczema, acne, and athlete's foot.

Abstract: A novel polypeptide which has an excellent angiogenesis-inducing activity and an excellent antibacterial activity, and a novel angiogenesis-inducing agent which contains the polypeptide as an effective ingredient or a novel agent for treating a wound(s) which contains the polypeptide as an effective ingredient are disclosed. The polypeptide of the present invention is a polypeptide whose amino acid sequence is shown in any one of SEQ ID NOs:1 to 6, 8 and 10. The angiogenesis-inducing agent which contains the polypeptide of the present invention as an effective ingredient is useful for the prevention, amelioration or treatment of a disease such as a burns, decubitus, wound, skin ulcer, leg ulcer, diabetic ulcer, occlusive arterial disease and arteriosclerosis obliteran.

Abstract: A composition including an artificially synthesized antimicrobial peptide that is not present as a mature peptide in nature. The composition includes an artificially synthesized peptide that has an antimicrobial activity against at least one strain of bacteria or fungi and includes an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6 or an amino acid sequence formed by substituting, deleting and/or adding one, two or three amino acid residues in/from/to the amino acid sequence, and further including at least one species of pharmaceutically acceptable carrier.

Abstract: Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus neoformans, roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of Cryptococcus neoformans, roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited.

Abstract: The present invention provides synthetic antibacterial peptides comprising a sequence at least 80% identical to a sequence shown in SEQ ID NO: 2 or the diastereomer thereof with a sequence shown in SEQ ID NO: 3 or pharmaceutical compositions thereof. Also provided are methods for reducing the severity of microbe-induced inflammation and for stimulating wound healing via the synthetic antibacterial peptides. Further provided is a device having a surface with a coating comprising the synthetic antibacterial peptides.

Abstract: Disclosed are amphiphilic peptides. Also disclosed are methods of treating proliferative disease, bacterial infection, viral infection and fungal infection, endotoxin neutralization and a method of removing biofilm. Also disclosed is the use of the amphiphilic peptides.

Abstract: Provided is a system for protecting plants from attack by pests, including pathogens such as fungi. Specifically, a plant defensin is provided in conjunction with a protease inhibitor protects a plant from pest attack or reduces severity of an attack.

Abstract: The invention relates to a method of controlling or combating microbial organism by applying an antimicrobial peptide to the microbial organisms, wherein said antimicrobial peptide derived from Lilium ‘Stargazer’ glycine-rich protein 1. In addition, the present invention provides an antimicrobial composition comprising an antimicrobial peptide of the invention, an additional biocidal agent and pharmaceutically acceptable vehicles, excipients, diluents, and adjuvants.

Abstract: The present invention relates to a method for the purification of cyclopeptides of general formula (3) by means of a silicate.

Abstract: The present invention relates to novel Prothymosin Alpha (ProT?) variants that are capable of inducing cell-mediated immune responses. These variants lack a nuclear localization signal and the proliferative oncogenic activity previously attributed to ProT?. The variants of the invention are used in methods of treating, for example, viral infections, bacterial infections, fungal infections, cancer, ischemia and myeloproliferative blood disorders. Administration of a ProT? variant to a subject in a therapeutically effective amount treats the infection or disease.

Abstract: The disclosure describes collagen constructs comprising antifungal agents, preferably, copper, and related methods.

Abstract: Novel peptoid oligomers are disclosed that have a formula represented by the following formula I: The peptoids demonstrate antimicrobial activity and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals including humans where microbial invasion is involved. The present cyclic and linear peptoids are particularly valuable as their effect is rapid, broad in spectrum and mostly indifferent to resistance provoked by standard antibiotics.

Abstract: The present invention relates to active compound combinations for reducing the damage of plants and plant parts as well as losses in harvested fruits or vegetables caused by insects, nematodes or phytopathogens and which have fungicidal or nematicidal or insecticidal activity including any combination of the three activities, in particular within a composition, which comprises (A) Fluopyram and (B) one biological control agent, in particular bacteria, fungi or yeasts, protozoa, viruses, entomopathogenic nematodes, inoculants, botanicals and products produced by microorganisms including proteins or secondary metabolites. Moreover, the invention relates to a method for curatively or preventively controlling insects, nematodes or phytopathogens on the plant, plant parts, harvested fruits or vegetables, to the use of a combination according to the invention for the treatment of seed, to a method for protecting a seed and not at least to the treated seed.

Abstract: Disclosed is the method of treating keratits in a subject thereof comprising administering into the subject an amphiphilic peptides of the present disclosure. Also disclosed are methods of removing biofilm from cornea.

Abstract: The invention provides human secreted proteins (SECP) and polynucleotides which identify and encode SECP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of SECP.

Abstract: The present invention relates to the use of a polypeptides, comprising repeats of a peptide derived from a Heparan Sulphate Proteoglycan (HSPG) receptor binding region of an apolipoprotein, for treating or preventing a fungal and/or protist infection. The invention further relates to the use of such peptides for treating or preventing the contamination of surfaces or objects with such peptides.